Find policies, billing codes, payers, states, and providers
HCPCS J9000: Doxorubicin Hydrochloride Injection, 10 mg
HCPCS Level II code J9000 denotes a 10 mg vial of doxorubicin hydrochloride for injection, a commonly used anthracycline chemotherapy agent. Nationally, this code is central to oncology billing for parenteral chemotherapy delivered in outpatient infusion centers and hospital outpatient departments. Accurate coding of J9000 influences drug cost reporting, utilization tracking, and payer reimbursement for systemic cancer therapies.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, common sites of service, and payer coverage considerations. The publication summarizes typical billing practices, related HCPCS codes (including lipid formulation variants), and the ICD-10 diagnoses commonly associated with doxorubicin use in oncology care.
This resource provides national benchmarks and policy-relevant information useful for billing specialists, practice managers, and oncology clinicians seeking clear code definitions, common clinical indications, and how J9000 fits into broader chemotherapy billing workflows.
Customize your policy alerts
Sign up for hcpcs J9000 policy alerts
Get alerted when payer policies referencing J9000 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J9000 represents an injection of doxorubicin hydrochloride, 10 mg. This medication is an anthracycline chemotherapeutic agent used in the systemic treatment of various malignant neoplasms.
Service Type: Parenteral chemotherapy administration
Typical Site of Service: Outpatient infusion center or hospital outpatient department
National Reimbursement Benchmarks
National commercial rates for J9000 cluster around BUCA’s average commercial benchmark of $5.3, with notable variation among major carriers. Blue Cross Blue Shield shows a relatively tight interquartile spread (P75–P25 = $1.8), and UnitedHealth Group is also compact (spread = $1.2), indicating concentration near their medians. Aetna and Cigna display wider dispersion driven by higher upper tails; Aetna’s interquartile spread is $2.4 while Cigna’s is $1.0, but Aetna’s maximum rate ($92.9) and Cigna’s high maximum ($66.0) create broader overall variability beyond the IQRs.
Comparing central tendencies, most payers cluster near BUCA’s mean of $5.3 and Cigna and Aetna share median values at $3.0, whereas Blue Cross Blue Shield and UnitedHealth Group medians are slightly higher at $4.5 and $3.2 respectively. The tightest IQRs belong to UnitedHealth Group and Blue Cross Blue Shield, while Aetna exhibits the widest overall dispersion when considering its extreme maximum.